FY2025 · ended Dec 31, 2025 · Revenue $72,102, +0.0% YoY · Filed Mar 27, 2026
Silo Pharma, Inc. (SILO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $72,102 and a net loss of $4.2 million.
Revenue (TTM)
$54,077
-25.0% vs year-ago TTM
Net income (TTM)
$-4.47M
+8.6% vs year-ago TTM
Operating cash flow (TTM)
$-3.34M
+35.6% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-0.51
+74.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
14.17M
+215.9% vs prior year
Net cash
—
Operating margin
-8250.5%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SILO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Sarasota, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1514183
- Former names
- Uppercut Brands, Inc. (until Aug 14, 2020); Point Capital, Inc. (until May 14, 2019); Gold Swap Inc (until Jan 7, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $72,102 | $72,102 | $72,102 | — | — |
| Operating income | -$4.3M | -$4.7M | -$3.9M | -$3.6M | -$2.7M |
| Net income | -$4.2M | -$4.4M | -$3.7M | -$3.9M | $3.9M |
| Diluted EPS | -$0.50 | -$1.19 | — | — | $0.04 |
| Operating cash flow | -$4.7M | -$3.8M | -$3.2M | -$3.5M | -$2.3M |
| Total assets | $7.6M | $7.4M | $7.7M | $11.6M | $10.5M |
| Total liabilities | $1.3M | $2.4M | $1.6M | $1.3M | $1.4M |
| Stockholders' equity | $6.3M | $5.0M | $6.2M | $10.3M | $9.1M |
| Cash and investments | $6.9M | $7.1M | $7.7M | $11.4M | $9.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 14, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 2, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Aug 19, 2026 | Aug 18, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Aug 17, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jul 13, 2026 | Jul 9, 2026 |
All 378 Silo Pharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.